Clinical Trials Logo

Clinical Trial Summary

The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, or stinging) associated with sunlight exposure in subjects with EPP or XLP aged 12-75.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04402489
Study type Interventional
Source Mitsubishi Tanabe Pharma America Inc.
Contact
Status Completed
Phase Phase 3
Start date June 1, 2020
Completion date July 26, 2022

See also
  Status Clinical Trial Phase
Completed NCT01688895 - Erythropoietic Protoporphyrias: Studies of the Natural History, Genotype-Phenotype Correlations, and Psychosocial Impact
Completed NCT02979249 - Oral Iron for Erythropoietic Protoporphyrias N/A
Active, not recruiting NCT05005975 - Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) Phase 3